Uric acid
Based on 23 publication(s) in Google Scholar
Uric acid is an orally active oxygen free radical scavenger that helps maintain stable blood pressure and combat oxidative stress. Uric acid can scavenge ROS, such as singlet oxygen and peroxynitrite, and inhibit lipid peroxidation. Uric acid can be used as a modeling agent in research on hyperuricemia-induced hypertension models.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.92%
- CAS. Nr.: 69-93-2
- Formel: C5H4N4O3
- Molecular Weight:168.11
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Uric acid
More- Nature. 2025 Jul;643(8070):192-200. [Abstract]
- J Adv Res. 2025 Nov 7:S2090-1232(25)00877-X. [Abstract]
- J Adv Res. 2025 Jul 14:S2090-1232(25)00544-2. [Abstract]
- Adv Sci (Weinh). 2025 Apr;12(16):e2415041. [Abstract]
- Cell Rep Med. 2024 Aug 20;5(8):101690. [Abstract]
- Cell Mol Biol Lett. 2025 Oct 2;30(1):109. [Abstract]
- Phytomedicine. 2026 May 14:157:158292. [Abstract]
- J Hazard Mater. 2024 Dec 5:480:135938. [Abstract]
- J Ginseng Res. 2025 Jul;49(4):426-437. [Abstract]
- J Agric Food Chem. 2025 Aug 27. [Abstract]
- Drug Des Devel Ther. 2025 Jul 30:19:6573-6585. [Abstract]
- Respir Res. 2025 May 24;26(1):196. [Abstract]
- Int J Mol Sci. 2022 Jun 20;23(12):6860. [Abstract]
- Arab J Chem. 2024 Jul 20.
- BMC Biotechnol. 2026 Apr 15;26(1):69. [Abstract]
- Genes Immun. 2025 Aug;26(4):365-375. [Abstract]
- Drug Dev Res. 2020 Nov;81(7):859-866. [Abstract]
- Front Biosci (Landmark Ed). 2025 Nov 26;30(11):46700. [Abstract]
- Exp Biol Med. 2022 Jan;247(2):174-183. [Abstract]
- BMC Neurol. 2023 Dec 16;23(1):444. [Abstract]
- Biomed Pharmacother. 2025 Dec:193:118745. [Abstract]
- Research Square Preprint. 2023 Jul 28.
- Research Square Preprint. 2022 Feb.
Customer Validation & Images
-
IF
-
Bio/Physico-chemical Assay
-
WB
-
IF
-
Cell Proliferation/Viability Assay
Alle Endogenous Metabolite Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
|
Human Endogenous Metabolite |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEK293 | EC50 |
0.3 mM
Compound: 1175
|
Substrate uptake by the Glucose Transporter Type 9 (GLUT9, SLC2A9) as assessed by the fluorescent FLIPR membrane potential dye in HEK-293 cells stably transfected with SLC2A9 isoform 1
Substrate uptake by the Glucose Transporter Type 9 (GLUT9, SLC2A9) as assessed by the fluorescent FLIPR membrane potential dye in HEK-293 cells stably transfected with SLC2A9 isoform 1
|
10.5281/zenodo.7360607 |
| HEK293 | EC50 |
0.3 mM
Compound: 1175
|
Substrate uptake by the Glucose Transporter Type 9 (GLUT9, SLC2A9) as assessed by the fluorescent FLIPR membrane potential dye in HEK-293 cells stably transfected with SLC2A9 isoform 1 (PubChem AID: 1794831)
Substrate uptake by the Glucose Transporter Type 9 (GLUT9, SLC2A9) as assessed by the fluorescent FLIPR membrane potential dye in HEK-293 cells stably transfected with SLC2A9 isoform 1 (PubChem AID: 1794831)
|
10.5281/zenodo.7360607 |
Uric acid mitigates Indomethacin (HY-14397)‑caused lipid peroxidation, reduces ROS production and improves cell viability in Caco‑2 cells upon co‑treatment with 200 μM Indomethacin via its antioxidant activity[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Note:
Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.
Administration: Diet containing 2% oxonic acid (OA, a uricase inhibitor) + drinking water containing 6 mg/dl uric acid
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS. Nr. 69-93-2
-
Appearance Solid
-
Molecular Weight 168.11
-
Formel C5H4N4O3
-
Color White to off-white
-
SMILES
O=C(N1)NC2=C(NC(N2)=O)C1=O
-
Structure Classification
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (23)
-
Journal Impact Factor
-
Most Recent
-
Nature
2025 Jul;643(8070):192-200. PMID: 39695227 -
J Adv Res
Hyperuricemia increases susceptibility to chronic kidney injury exacerbation via autophagic flux blockade-mediated ammonia death pathway. [Abstract]2025 Nov 7:S2090-1232(25)00877-X. PMID: 41205802 -
J Adv Res
Tussilagone attenuated cigarette smoke-induced chronic obstructive pulmonary disease through regulating Nrf2 and NF-κB/NLRP3 inflammasome via directly targeting cysteine 434 of KEAP1. [Abstract]2025 Jul 14:S2090-1232(25)00544-2. PMID: 40669599 -
Adv Sci (Weinh)
Metabolomic and Cellular Mechanisms of Drug-Induced Ototoxicity and Nephrotoxicity: Therapeutic Implications of Uric Acid Modulation. [Abstract]2025 Apr;12(16):e2415041. PMID: 40041973
Uric acid purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Apr;12(16):e2415041. [Abstract]
Immunofluorescence analysis of hair cells (HCs) with or without Uric acid (UA; 1, 2, 4 mM) at different concentrations for 24 h. Myosin 7a positive HCs are shown in red, and nuclei are labeled in blue.
-
Cell Rep Med
The SGLT2 inhibitor dapagliflozin ameliorates renal fibrosis in hyperuricemic nephropathy. [Abstract]2024 Aug 20;5(8):101690. PMID: 39168099 -
Cell Mol Biol Lett
2025 Oct 2;30(1):109. PMID: 41039223
Uric acid purchased from MedChemExpress. Usage Cited in: Cell Mol Biol Lett. 2025 Oct 2;30(1):109. [Abstract]
The TEAC (top) and MDA content (bottom) were measured after co-treatment with RSL3 (MHCC97H: 0.5 µM; SJSA-1: 1 µM; LoVo: 5 µM) and Uric acid (UA; 500 µM) for 24 h. TEAC values were normalized to Trolox standards.
-
Phytomedicine
Cinchonain Ia inhibits uric acid reabsorption by binding to the TRP-459 residue of the GLUT9 protein. [Abstract]2026 May 14:157:158292. PMID: 42176511 -
J Hazard Mater
Environmentally relevant concentrations of perfluorobutane sulfonate impair locomotion behaviors and healthspan by downregulating mitophagy in C. elegans. [Abstract]2024 Dec 5:480:135938. PMID: 39326150
Uric acid purchased from MedChemExpress. Usage Cited in: J Hazard Mater. 2024 Dec 5:480:135938. [Abstract]
Representative Western blots of PPARγ and quantification of its protein level in different groups of HK2 cells with Uric acid (UA; 400 μM; 48 h).
Uric acid purchased from MedChemExpress. Usage Cited in: J Hazard Mater. 2024 Dec 5:480:135938. [Abstract]
Representative IF images of PPARγ (green)/DAPI (blue) in HK2 cells with Uric acid (UA; 400 μM; 48 h).
Uric acid purchased from MedChemExpress. Usage Cited in: J Hazard Mater. 2024 Dec 5:480:135938. [Abstract]
Representative cell viability detected by CCK-8 in different groups of HK2 cells. Bixin (0-640 μM) without or with 400 μM Uric acid (UA) for 48 h.
-
J Ginseng Res
Ginsenoside Rg5 modulates the TLR4 and BCL-2 pathways by inhibiting NOX1, thereby alleviating inflammation, apoptosis and pyroptosis in hyperuricemia nephropathy. [Abstract]2025 Jul;49(4):426-437. PMID: 40621077 -
J Agric Food Chem
Pachymic Acid Ameliorates Fructose-Driven Hyperuricemic Nephropathy in Mice by Suppressing Ferroptosis via Activating Nrf2/GPX-4 Pathway. [Abstract]2025 Aug 27. PMID: 40864644 -
Drug Des Devel Ther
17(R)-RvD1 Ameliorates Liver Injury in Hyperuricemia Through Inhibiting Pyroptosis via NF-κB Signaling Pathway. [Abstract]2025 Jul 30:19:6573-6585. PMID: 40756265 -
Respir Res
Phenylacetylglutamine produced from injury lung alveolar epithelial cells promotes the function of BMSCs by regulating NONRATT006276.2/Mapt pathway. [Abstract]2025 May 24;26(1):196. PMID: 40413470 -
Int J Mol Sci
A Dual-Acting Nitric Oxide Donor and Phosphodiesterase 5 Inhibitor Activates Autophagy in Primary Skin Fibroblasts. [Abstract]2022 Jun 20;23(12):6860. PMID: 35743299 -
-
BMC Biotechnol
Mechanistic insights into how cichoriin inhibits P2Y14R to suppress MSU-induced gouty inflammation. [Abstract]2026 Apr 15;26(1):69. PMID: 41987170 -
Genes Immun
S-nitrosylated NEDD4 exacerbates gouty arthritis by upregulating NOD1 to induce pyroptosis. [Abstract]2025 Aug;26(4):365-375. PMID: 40594913 -
Drug Dev Res
The mechanism of Arhalofenate in alleviating hyperuricemia-Activating PPARγ thereby reducing caspase-1 activity. [Abstract]2020 Nov;81(7):859-866. PMID: 32506648 -
Front Biosci (Landmark Ed)
P110 Inhibits DRP1/FIS1-Mediated Mitochondrial Fission to Alleviate Uric Acid-Induced Apoptosis in HK-2 Cells. [Abstract]2025 Nov 26;30(11):46700. PMID: 41351411 -
Exp Biol Med
CTRP3 protects against uric acid-induced endothelial injury by inhibiting inflammation and oxidase stress in rats. [Abstract]2022 Jan;247(2):174-183. PMID: 34601891 -
BMC Neurol
Integrative analysis of purine metabolites and gut microbiota in patients with neuromyelitis optica spectrum disorders after mycophenolate mofetil treatment. [Abstract]2023 Dec 16;23(1):444. PMID: 38102573 -
Biomed Pharmacother
Bixin prevents tubulointerstitial fibrosis in hyperuricemic nephropathy via promoting PPARγ-NLRP3 interaction. [Abstract]2025 Dec:193:118745. PMID: 41232352 -
-
Lösungsmittel & Löslichkeit
1M NaOH : 8.33 mg/mL (49.55 mM; ultrasonic and warming and adjust pH to 12 with 1M NaOH and heat to 60°C)
H2O : 6.25 mg/mL (37.18 mM; ultrasonic and adjust pH to 11 with 1 M NaOH)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 0.5% CMC-Na/saline water
Solubility: 10 mg/mL (59.48 mM); Suspended solution; Need ultrasonic
Protokoll
Human colon carcinoma cells (Caco-2) are used and grown in Eagle’s minimum essential medium supplemented with 10% FBS, 1% non-essential amino acid mixture, and 1% Pen-Strep at 37°C in a humidified atmosphere with 5% CO2. Caco-2 cells are incubated with indomethacin in the presence or absence of Uric acid for 24 or 48 hours[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
To evaluate the effect of oral administration of Uric acid on NSAID-induced enteropathy, mice are given Uric acid (2.5, 10, 25, 100, or 250 mg/kg body weight) suspended in 0.5% carboxymethyl cellulose orally at 30 minutes before, and 12 hours after indomethacin or vehicle treatment. To evaluate the effect of intraperitoneal administration of inosinic acid plus potassium oxonate on NSAID-induced enteropathy, mice are given inosinic acid (500 mg/kg body weight) plus potassium oxonate (250 mg/kg body weight) 24 intraperitoneally at 30 minutes before, and 12 hours after indomethacin or vehicle treatment[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Reinheit & Dokumentation
-
Data Sheet (291 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Wang Q, et al. Recent Progress on Uric Acid Detection: A Review. Crit Rev Anal Chem. 2020;50(4):359-375. [Content Brief]
[2]. Yasutake Y, et al. Uric acid ameliorates indomethacin-induced enteropathy in mice through its antioxidant activity. J Gastroenterol Hepatol. 2017 Nov;32(11):1839-1845. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / 1M NaOH | 1 mM | 5.9485 mL | 29.7424 mL | 59.4849 mL | 148.7122 mL |
| 5 mM | 1.1897 mL | 5.9485 mL | 11.8970 mL | 29.7424 mL | |
| 10 mM | 0.5948 mL | 2.9742 mL | 5.9485 mL | 14.8712 mL | |
| 15 mM | 0.3966 mL | 1.9828 mL | 3.9657 mL | 9.9141 mL | |
| 20 mM | 0.2974 mL | 1.4871 mL | 2.9742 mL | 7.4356 mL | |
| 25 mM | 0.2379 mL | 1.1897 mL | 2.3794 mL | 5.9485 mL | |
| 30 mM | 0.1983 mL | 0.9914 mL | 1.9828 mL | 4.9571 mL | |
| 1M NaOH | 40 mM | 0.1487 mL | 0.7436 mL | 1.4871 mL | 3.7178 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Uric acid Related Classifications
HY-B2130 Related Classifications
Powered by Bioz